U.S. markets open in 3 hours 34 minutes

Appili Therapeutics Inc. (APLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.03900.0000 (0.00%)
At close: 12:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0390
BidN/A x N/A
AskN/A x N/A
Day's Range0.0390 - 0.0390
52 Week Range0.0350 - 0.8450
Avg. Volume18,449
Market Cap4.305M
Beta (5Y Monthly)0.92
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for APLIF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    NKTR: What does Argus have to say about NKTR?NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Business Wire

    Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

    HALIFAX, Nova Scotia, September 22, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.

  • Zacks Small Cap Research

    APLIF: Advancing Multiple Programs to Combat Infectious Diseases…

    By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT Business Update New Late-Stage Program in Cutaneous Leishmaniasis In April 2022, Appili Therapeutics Inc. (OTC:APLIF) (TSX:APLI.TO) announced the addition of ATI-1801, a late stage clinical program to treat cutaneous leishmaniasis. The product, a topical formulation of paromomycin, was licensed from the U.S.

  • Business Wire

    Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

    HALIFAX, Nova Scotia, August 12, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.